KR890701757A - Recombinant apox virus - Google Patents

Recombinant apox virus

Info

Publication number
KR890701757A
KR890701757A KR1019890700753A KR890700753A KR890701757A KR 890701757 A KR890701757 A KR 890701757A KR 1019890700753 A KR1019890700753 A KR 1019890700753A KR 890700753 A KR890700753 A KR 890700753A KR 890701757 A KR890701757 A KR 890701757A
Authority
KR
South Korea
Prior art keywords
virus
antigen
vertebrate
abipox
pathogen
Prior art date
Application number
KR1019890700753A
Other languages
Korean (ko)
Other versions
KR970011149B1 (en
Inventor
파올렛티 엔조
Original Assignee
원본미기재
헬스 리서치 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890701757(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 헬스 리서치 인코오퍼레이티드 filed Critical 원본미기재
Publication of KR890701757A publication Critical patent/KR890701757A/en
Application granted granted Critical
Publication of KR970011149B1 publication Critical patent/KR970011149B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음No content

Description

재조합 아비폭스 바이러스Recombinant apox virus

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (39)

척추동물에서 유전자 생성물을 발현시키는 방법으로서, 척추동물에서 바이러스의 증식적인 복제없이 유전자 생성물을 코드화하고 발현하는 DNA를 포함하는 재조합 바이러스로 척추동물을 접종하는 것으로 이루어지는 방법.A method of expressing a gene product in a vertebrate, the method comprising inoculating the vertebrate with a recombinant virus comprising DNA encoding and expressing the gene product without proliferative replication of the virus in the vertebrate. 제1항에 있어서, 상기 바이러스가 폭스 바이러스인 것을 특징으로 하는 방법.The method of claim 1 wherein the virus is a pox virus. 제2항에 있어서, 상기 바이러스가 아비폭스 바이러스인 것을 특징으로 하는 방법.The method of claim 2, wherein the virus is an Abipox virus. 제3항에 있어서, 상기 아비폭스 바이러스가 파울폭스 바이러스와 카나리아폭스 바이러스로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 방법.4. The method of claim 3, wherein said Abipox virus is selected from the group consisting of Paulpox virus and Canary pox virus. 제1항에 있어서, 척추동물에 피하로, 피부내로, 근육내로, 경구로 또는 난내로 바이러스를 도입함으로써 척추동물이 접종되는 것을 특징으로 하는 방법.The method of claim 1, wherein the vertebrate is inoculated with the virus by introducing the virus subcutaneously, into the skin, intramuscularly, orally or into the egg. 척추동물에서 항원에 대한 면역학적 반응을 유도하는 방법으로서, 척추동물에서 바이러스의 증식적 복제없이 항원을 코드화하고 발현하는 DNA를 포함하는 재조합 바이러스로 척추동물을 접종하는 것으로 이루어 지는 방법.A method of inducing an immunological response to an antigen in a vertebrate, the method comprising inoculating the vertebrate with a recombinant virus comprising DNA encoding and expressing the antigen without proliferative replication of the virus in the vertebrate. 제6항에 있어서, 상기 바이러스가 폭스 바이러스인 것을 특징으로 하는 방법.7. The method of claim 6, wherein said virus is a pox virus. 제7항에 있어서, 상기 바이러스가 아비폭스 바이러스인 것을 특징으로 하는 방법.8. The method of claim 7, wherein said virus is an abipox virus. 제8항에 있어서, 상기 아비폭스 바이러스가 파울폭스 바이러스와 카나리아폭스 바이러스로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 방법.10. The method of claim 8, wherein said Abipox virus is selected from the group consisting of Paulpox virus and Canary pox virus. 제6항에 있어서, 척추동물에 피하로, 피부내로, 근육내로, 경구로 또는 난내로 바이러스를 도입함으로써 척추동물이 접종되는 것을 특징으로 하는 방법.The method of claim 6, wherein the vertebrate is inoculated with the virus by introducing the virus subcutaneously, into the skin, intramuscularly, orally or into the egg. 척추동물에서 척추동물 병원체에 대한 면역학적 반응을 유도하는 방법으로서, 척추동물에서 바이러스의 증식적 복제없이 병원체의 항원을 코드화하고 발현하는 DNA를 포함하는 재조합 바이러스로 척추동물을 접종하는 것으로 이루어지는 방법.A method of inducing an immunological response to a vertebrate pathogen in a vertebrate, comprising inoculating the vertebrate with a recombinant virus comprising DNA encoding and expressing the antigen of the pathogen without proliferative replication of the virus in the vertebrate. 제11항에 있어서, 상기 바이러스가 폭스 바이러스인 것을 특징으로 하는 방법.12. The method of claim 11, wherein said virus is a pox virus. 제12항에 있어서, 상기 바이러스가 아비폭스 바이러스인 것을 특징으로 하는 방법.13. The method of claim 12, wherein said virus is an Abipox virus. 제13항에 있어서, 상기 아비폭스 바이러스가 파울폭스 바이러스와 카나리아 폭스 바이러스로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 방법.The method of claim 13, wherein said Abipox virus is selected from the group consisting of Paulpox virus and Canary pox virus. 제11항에 있어서, 상기 척추동물이 포유류이고 상기 척추동물 병원체가 포유류 병원체인 것을 특징으로 하는 방법.12. The method of claim 11, wherein said vertebrate is a mammal and said vertebrate pathogen is a mammalian pathogen. 제15항에 있어서, 항원이 광견병 G항원, 소백혈병 바이러스의 gP51,30 엔벨로프 항원, 고양이 백혈병 바이러스의 FeLV 엔벨로프항원 및 단순 포진 바이러스의 당단백질 D항원으로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 방법.16. The method of claim 15, wherein the antigen is selected from the group consisting of rabies G antigen, gP51,30 envelope antigen of bovine leukemia virus, FeLV envelope antigen of feline leukemia virus, and glycoprotein D antigen of herpes simplex virus. 제15항에 있어서, 포유류가 개, 고양이, 마우스, 토끼, 소, 양 및 돼지로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 방법.The method of claim 15, wherein the mammal is selected from the group consisting of dogs, cats, mice, rabbits, cows, sheep and pigs. 제11항에 있어서, 척추동물에 피하로, 피부내로, 근육내로, 경구로 또는 난대로 바이러스를 도입함으로써 척추동물이 접종되는 것을 특징으로 하는 방법.The method of claim 11, wherein the vertebrate is inoculated by introducing the virus subcutaneously, into the skin, intramuscularly, orally or eggshell. 척추동물에서 척추동물 병원체에 대한 면역학적 반응의 유도방법으로서, 병원체의 항원을 코드화하고 발현하는 DNA를 포함하는 재조합 아비폭스 바이러스로 척추동물을 접종하는 것으로 이루어지는 방법.A method of inducing an immunological response to vertebrate pathogens in vertebrates, the method comprising inoculating a vertebrate with a recombinant Apox virus comprising DNA encoding and expressing an antigen of the pathogen. 제19항에 있어서, 상기 척추동물이 포유류이고 상기 척추동물 병원체가 포유류 병원체인 것을 특징으로 하는 방법.20. The method of claim 19, wherein said vertebrate is a mammal and said vertebrate pathogen is a mammalian pathogen. 제19항에 있어서, 항원이 광견병 G항원, 소백혈병 바이러스의 gP51,30 엔벨로프 항원, 고양이 백혈병 바이러스인 FeLV 엔벨로프 항원 및 단순포진 바이러스의 당단백질 D항원으로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 방법.20. The method of claim 19, wherein the antigen is selected from the group consisting of rabies G antigen, gP51,30 envelope antigen of bovine leukemia virus, FeLV envelope antigen of feline leukemia virus, and glycoprotein D antigen of herpes simplex virus. 제19항에 있어서, 상기 척추동물이 조류이고 상기 척추동물 병원체가 조류 병원체인 것을 특징으로 하는 방법.20. The method of claim 19, wherein said vertebrate is a bird and said vertebrate pathogen is a bird pathogen. 제22항에 있어서, 상기 항원이 조류 인플루엔자 혈구응집소 항원, 뉴캐슬 질병 바이러스의 융합 단백질 항원, 로우스 관련 바이러스의 RAV-1 엔벨로프 항원, 조류 인플루엔자 바이러스의 핵단백질 항원, 감염성 기관지염 바이러스의 매트릭스 항원 및 감염성 기관지염 바이러스의 페플로머 항원으로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 방법.23. The method of claim 22, wherein said antigen is avian influenza hemagglutinin antigen, a fusion protein antigen of Newcastle Disease Virus, a RAV-1 envelope antigen of Loose-associated virus, a nucleoprotein antigen of avian influenza virus, a matrix antigen of infectious bronchitis virus, and infectious The bronchitis virus is selected from the group consisting of peplomer antigens. 아비폭스 게놈의 비필수 영역에 비-아비폭스 기원의 DNA를 함유하고 있는 재조합 아비폭스 바이러스.A recombinant Apox virus containing DNA of non-Abipox origin in a non-essential region of the Abipox genome. 제24항에 있어서, 추가로 상기 DNA를 발현하기 위한 비-아비폭스 촉진유전자를 함유하는 것을 특징으로 하는 바이러스.25. The virus of claim 24, further comprising a non-Abipox promoter, for expressing said DNA. 제25항에 있어서, 비-아비폭스 촉진유전자가 백시니아 촉진유전자인 것을 특징으로 하는 바이러스.The virus of claim 25, wherein the non-Abipox promoter is a vaccinia promoter. 제26항에 있어서, 상기 백시니아 촉진유전자가 HH, 11K, 및 Pi로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 바이러스.27. The virus of claim 26, wherein said vaccinia promoter is selected from the group consisting of HH, 11K, and Pi. 제25항에 있어서, 비-아비폭스 촉진유전자가 엔토모폭스 촉진유전자인 것을 특징으로 하는 바이러스.The virus of claim 25, wherein the non-Abipox promoter is an Entomopox promoter. 제24항에 있어서, 추가로 상기 DNA를 발현하기 위한 아비폭스 촉진유전자를 함유하는 것을 특징으로 하는 바이러스.25. The virus of claim 24, further comprising an abipox promoter for expressing said DNA. 제24항에 있어서, 상기 DNA가 포유류 병원체의 항원을 코드하는 것을 특징으로 하는 바이러스.The virus of claim 24, wherein said DNA encodes an antigen of a mammalian pathogen. 제30항에 있어서, 항원이 광견병 항원, 광견병 G항원, 소백혈병 바이러스 gp51,30 엔벨로프 항원, 고양이 백혈병 바이러스의 FeLV 엔벨로프 항원 및 단순포진 바이러스의 당단백질 D항원으로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 바이러스.The antigen of claim 30, wherein the antigen is selected from the group consisting of rabies antigen, rabies G antigen, small leukemia virus gp51,30 envelope antigen, FeLV envelope antigen of feline leukemia virus and glycoprotein D antigen of herpes simplex virus. virus. 제24항에 있어서, 상기 DNA 가 조류 병원체의 항원을 코드하는 것을 특징으로 하는 바이러스.The virus of claim 24, wherein said DNA encodes an antigen of an avian pathogen. 제32항에 있어서, 상기 항원이 조류 인플루엔자 혈구응집소항원, 뉴캐슬 질병 바이러스의 융합 단백질 항원, 로우스 관련 바이러스의 RAV-1 엔벨로프 항원, 조류 인플루엔자 바이러스의 핵단백질 항원, 감염성 기관지염 바이러스의 매트릭스 항원 및 감염성 기관지염 바이러스의 페플로머 항원으로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 바이러스.33. The method of claim 32, wherein said antigen is avian influenza hemagglutinin antigen, a fusion protein antigen of Newcastle disease virus, a RAV-1 envelope antigen of Loose-associated virus, a nucleoprotein antigen of avian influenza virus, a matrix antigen of infectious bronchitis virus, and infectious The virus characterized in that it is selected from the group consisting of the peplomer antigen of bronchitis virus. 제24항에 있어서, 상기 아비폭스 바이러스가 파울폭스인 것을 특징으로 하는 바이러스.25. The virus of claim 24, wherein said Abipox virus is foulox. 제24항에 있어서, 상기 아비폭스 바이러스가 카나리아폭스인 것을 특징으로 하는 바이러스.The virus of claim 24, wherein the Abipox virus is canary fox. 어떠한 공급원으로부터의 DNA와 상기 DNA를 발현하는 엔토모폭스 촉진유전자를 함유하는 있는 재조합 폭스 바이러스.A recombinant pox virus containing DNA from any source and an Entomopox promoter that expresses the DNA. 제36항에 있어서, 상기 바이러스가 아비폭스 바이러스인 것을 특징으로 하는 바이러스.37. The virus of claim 36, wherein said virus is an Abipox virus. 제36항에 있어서, 상기 바이러스가 백시니아 바이러스인 것을 특징으로 하는 바이러스.37. The virus of claim 36, wherein said virus is a vaccinia virus. 어떠한 공급원으로부터의 DNA와 상기 DNA를 발현하기 위한 아비폭스 촉진유전자를 함유하고 있는 재조합 백시니아 바이러스Recombinant vaccinia virus containing DNA from any source and an Abipox promoter for expressing the DNA ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019890700753A 1987-08-28 1988-08-24 Recombinant avipox virus KR970011149B1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US9071187A 1987-08-28 1987-08-28
US11033587A 1987-10-20 1987-10-20
US110,335 1987-10-20
US18605488A 1988-04-25 1988-04-25
US186,054 1988-04-25
US23439088A 1988-08-23 1988-08-23
US090,711 1988-08-23
US234,390 1988-08-23
PCT/US1988/002816 WO1989003429A1 (en) 1987-08-28 1988-08-24 Recombinant avipox virus

Publications (2)

Publication Number Publication Date
KR890701757A true KR890701757A (en) 1989-12-21
KR970011149B1 KR970011149B1 (en) 1997-07-07

Family

ID=27492413

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890700753A KR970011149B1 (en) 1987-08-28 1988-08-24 Recombinant avipox virus

Country Status (17)

Country Link
JP (3) JP3348156B2 (en)
KR (1) KR970011149B1 (en)
AR (1) AR241939A1 (en)
AT (1) AT408549B (en)
AU (2) AU2427588A (en)
BE (1) BE1002134A5 (en)
CH (2) CH679933A5 (en)
DE (4) DE10399031I1 (en)
DK (1) DK175904B1 (en)
FR (1) FR2621487B1 (en)
GB (1) GB2217718B (en)
IL (1) IL87581A0 (en)
IT (1) IT1229484B (en)
LU (2) LU90951I2 (en)
NL (4) NL195051C (en)
NZ (1) NZ225970A (en)
WO (1) WO1989003429A1 (en)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399031I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
US5286639A (en) * 1987-09-16 1994-02-15 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
DE3813093A1 (en) * 1988-04-19 1989-11-09 Immuno Ag RECOMBINANT PLASMIDE, METHOD FOR PRODUCING A RECOMBINANT AVIPOX VIRUS, RECOMBINANT AVIPOX VIRUS, AND USE THEREOF
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
EP0353851B1 (en) * 1988-06-24 1994-01-19 Btg International Limited Fowlpox virus non-essential regions
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
CA2001001A1 (en) * 1988-10-21 1990-04-21 Matthew M. Binns Fowlpox virus promoter
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5204243A (en) * 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
FR2668064B1 (en) * 1990-10-23 1994-12-16 Transgene Sa PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF MALIGNANT TUMOR.
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
US5503834A (en) * 1990-11-20 1996-04-02 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
IE68404B1 (en) * 1990-11-20 1996-06-12 Virogenetics Corp Measles virus recombinant poxvirus vaccine
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5338679A (en) * 1991-01-08 1994-08-16 Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
KR100242671B1 (en) * 1991-03-07 2000-03-02 고돈 에릭 Genetically engineered vaccine strain
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
AU672581B2 (en) * 1991-03-07 1996-10-10 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5756101A (en) * 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
JPH06505397A (en) * 1991-03-20 1994-06-23 ヴァイロジェネティクス　コーポレイション malaria recombinant poxvirus
JPH06509235A (en) * 1991-07-26 1994-10-20 ヴァイロジェネティクス　コーポレイション Infectious Bursal Disease Virus Recombinant Poxvirus Vaccine
EP1380651A2 (en) * 1991-08-26 2004-01-14 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
US5443831A (en) * 1991-10-29 1995-08-22 University Of Delaware Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
US6497882B1 (en) 1992-01-13 2002-12-24 Syntro Corporation Recombinant swinepox virus
US6328975B1 (en) 1992-01-13 2001-12-11 Syntro Corporation Recombinant swinepox virus
ES2236684T3 (en) * 1992-01-13 2005-07-16 Virogenetics Corporation VACCINE OF THE VACCINIA RECOMBINANT VACCINIA FROM THE VIRUS OF THE DISEASE OF MAREK.
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US6033904A (en) * 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US6251403B1 (en) 1992-01-13 2001-06-26 Syntro Corporation Recombinant swinepox virus
US6127163A (en) * 1992-01-13 2000-10-03 Syntro Corporation Recombinant swinepox virus
EP0662139A1 (en) * 1992-09-21 1995-07-12 Chiron Corporation Recombinant retroviral vector against felv and/or fiv
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
AU727278B2 (en) * 1993-02-26 2000-12-07 Syntro Corporation Recombinant fowlpox viruses and uses thereof II
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
AU6299594A (en) * 1993-02-26 1994-09-14 Nippon Zeon Co., Ltd. Recombinant fowlpox virus s-fpv-043 and uses thereof
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
WO1999007869A1 (en) * 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (en) 1997-12-01 1999-06-22 Lintec Corp Cover tape for carrying chip body and sealing structure
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
CN1379819A (en) 1999-06-28 2002-11-13 俄克拉荷马州医学研究基金会 Catalytically active recombinant MEMAPSIN and methods of use thereof
CA2400842C (en) 2000-02-23 2013-01-15 Smithkline Beecham Biologicals S.A. Novel compounds
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
DE60239317D1 (en) 2001-01-12 2011-04-14 Novartis Vaccines & Diagnostic NUCLEIC ACID MUCOSAL IMMUNIZATION
PT1370668E (en) * 2001-03-08 2006-06-30 Akzo Nobel Nv VECTOR VACCINES BASED ON LEPORIPOX
JP4499311B2 (en) * 2001-04-27 2010-07-07 シャープ株式会社 Broadcast receiving terminal
EP1988097A1 (en) 2001-05-09 2008-11-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1409694A4 (en) 2001-07-05 2006-02-08 Chiron Corp Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
WO2003053220A2 (en) 2001-12-17 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
HUE026376T2 (en) 2003-01-06 2016-05-30 Corixa Corp Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US20070073048A1 (en) 2003-05-15 2007-03-29 Ying Lian Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
CA2636424A1 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
EP2397856B1 (en) 2006-03-14 2013-11-13 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
US8188214B2 (en) 2007-02-28 2012-05-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
WO2009049351A1 (en) 2007-10-15 2009-04-23 The University Of Queensland Construct system and uses therefor
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
AU2010203223B9 (en) 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
US8961989B2 (en) 2009-11-20 2015-02-24 Oregon Health & Science University Methods for producing an immune response to tuberculosis
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
US20150030586A1 (en) 2011-06-21 2015-01-29 Sarah Ellen Warren Compositions and methods for the therapy and diagnosis of cancer
BR112013032410A2 (en) 2011-06-24 2017-01-17 Epitogenesis Inc pharmaceutical compositions comprising a combination of selection vehicles, vitamins, tannins and flavonoids as antigen specific immunomodulators
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
ES2752190T3 (en) 2012-09-14 2020-04-03 Us Health Brachyury protein, adenoviral vectors encoding Brachyury protein and their use
SG10201912901YA (en) 2013-04-17 2020-02-27 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
CA2938828A1 (en) 2014-02-06 2015-08-13 Genzyme Corporation Compositions and methods for treating and preventing macular degeneration
JP7095990B2 (en) 2014-09-18 2022-07-05 シーダーズ－サイナイ メディカル センター Compositions and Methods for Treating Fibrosis
JP2018511655A (en) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Immunogenic compositions for use in vaccination against Bordetella
EP3283529B1 (en) 2015-04-17 2023-06-07 The General Hospital Corporation Agents, systems and methods for treating cancer
CN107708718B (en) 2015-04-22 2022-01-11 西达-赛奈医疗中心 Enterally delivered bitter oligopeptides for the treatment of type 2 diabetes
EP4276106A3 (en) 2015-05-13 2024-01-24 The United States of America as represented by the Secretary of the Department of Health and Human Services Methods and compositions for inducing an immune response using conserved element constructs
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP3313863B1 (en) 2015-06-29 2020-12-23 The Board of Trustees of the Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
EP3386593A4 (en) 2015-12-09 2019-07-24 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US10917454B1 (en) 2019-08-01 2021-02-09 Rohde & Schwarz Gmbh & Co. Kg System and method for ATC voice quality assurance
WO2023070072A1 (en) 2021-10-21 2023-04-27 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Retroelement-generated transcription factor decoys
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
WO2023183588A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK489481A (en) * 1980-11-10 1982-05-11 Searle & Co PLASMID VECTOR AND METHOD OF PRODUCING THEREOF
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
JPH0795954B2 (en) * 1982-11-30 1995-10-18 アメリカ合衆国 Method for producing recombinant poxvirus for expression of foreign gene
FR2563434B1 (en) * 1984-04-25 1986-07-25 Transgene Sa Rabies vaccine and process for its preparation
EP0190254A4 (en) * 1984-07-05 1987-03-09 Genex Corp Cloned gene and method for making and using the same.
DD235669A1 (en) * 1985-03-26 1986-05-14 Akad Wissenschaften Ddr METHOD FOR PRODUCING A BLV-CODED HUEL PROTEIN
US5032520A (en) * 1985-03-29 1991-07-16 National Research Development Corporation DNA sequences encoding infectious bronchitis virus spike protein
EP0213894A3 (en) * 1985-08-23 1987-10-21 Advanced Genetics Research Institute Defective viral particle vaccines and methods for their use
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
AU8075787A (en) * 1986-09-22 1988-04-07 Australian National University, The Recombinant poxviruses
WO1988002022A1 (en) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Recombinant poxviruses
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses
EP0284416B1 (en) * 1987-03-27 1995-02-22 Nippon Zeon Co., Ltd. Recombinant avipoxyvirus
DE10399031I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
GB8724885D0 (en) * 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
FR2632863B2 (en) * 1987-10-29 1990-08-31 Transgene Sa RECOMBINANT FOWLPOX VIRUS AND VACCINES DERIVED FROM SUCH VIRUSES
EP0353851B1 (en) * 1988-06-24 1994-01-19 Btg International Limited Fowlpox virus non-essential regions
DE4090351T1 (en) * 1989-03-08 1997-07-24 Health Research Inc Recombinant smallpox virus host selection system
EP0550553B1 (en) * 1990-09-25 2000-07-12 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line

Also Published As

Publication number Publication date
FR2621487A1 (en) 1989-04-14
DE10399031I1 (en) 2004-01-29
WO1989003429A1 (en) 1989-04-20
DK175904B1 (en) 2005-06-06
AU690210B2 (en) 1998-04-23
JP3826055B2 (en) 2006-09-27
CH679933A5 (en) 1992-05-15
NL300138I2 (en) 2004-03-01
JP2002186494A (en) 2002-07-02
JPH02500879A (en) 1990-03-29
NL300130I1 (en) 2003-09-01
NL195051C (en) 2003-07-01
CH679934A5 (en) 1992-05-15
IT8821772A0 (en) 1988-08-29
IT1229484B (en) 1991-09-03
NZ225970A (en) 1991-01-29
AR241939A1 (en) 1993-01-29
GB2217718A (en) 1989-11-01
AU1628895A (en) 1995-08-17
ATA900788A (en) 1995-05-15
DE10399032I1 (en) 2004-01-29
DE3890874C2 (en) 2003-03-13
LU90951I2 (en) 2003-01-15
DK203689D0 (en) 1989-04-27
KR970011149B1 (en) 1997-07-07
DE3890874C5 (en) 2005-10-20
NL300130I2 (en) 2005-11-01
NL8820679A (en) 1989-07-03
GB2217718B (en) 1992-05-20
LU91039I2 (en) 2003-11-05
IL87581A0 (en) 1989-01-31
NL300139I1 (en) 2004-02-02
FR2621487B1 (en) 1991-10-18
BE1002134A5 (en) 1990-07-24
NL300138I1 (en) 2004-02-02
JP3348156B2 (en) 2002-11-20
AT408549B (en) 2001-12-27
GB8908921D0 (en) 1989-08-02
JP2002348255A (en) 2002-12-04
DE10299049I1 (en) 2004-07-01
DK203689A (en) 1989-06-27
AU2427588A (en) 1989-05-02

Similar Documents

Publication Publication Date Title
KR890701757A (en) Recombinant apox virus
World Health Organization A revision of the system of nomenclature for influenza viruses: a WHO memorandum
Verwoerd et al. Orbiviruses
Memorandum A revision of the system of nomenclature for influenza viruses: a WHO memorandum
Öppling et al. Heterogeneity of the antigenic site responsible for the induction of neutralizing antibodies in infectious bursal disease virus
Garwes et al. Antigenicity of structural components from porcine transmissible gastroenteritis virus
Karaca et al. Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats
AR011216A1 (en) A VACCINE BASED ON SURFACE ANTIGENS AGAINST INFLUENZA, A METHOD FOR PREPARING IT, AND A METHOD FOR PREPARING SURFACE ANTIGEN PROTEINS FROM PROPAGATED INFLUENZA VIRUSES ON AN ANIMAL CELL CULTURE
KR910012233A (en) Turkey Recombinant Herpes Virus and Its Survival Vector Vaccines
CN1280504A (en) Vaccines with an LTB adjuvant
Spackman et al. The pathogenesis of turkey origin reoviruses in turkeys and chickens
ATE136788T1 (en) NEW VIRUS RESPONSIBLE FOR THE INFECTIOUS DISEASE BURSA FABRICIUS
Alldinger et al. In vivo and in vitro expression of canine distemper viral proteins in dogs and non-domestic carnivores
ES2109189B1 (en) VECTORS BASED ON RECOMBINANT DEFECTIVE VIRAL GENOMES AND THEIR USE IN THE FORMULATION OF VACCINES.
Joklik The reovirus particle
GB2264949A (en) Measles virus recombinant poxvirus vaccine
ES553758A0 (en) A METHOD FOR PREPARING PROTEINS THAT ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO VIRUSES ASSOCIATED WITH LYMPHADENOPATHY.
Cook et al. Epidemiology of infectious bronchitis virus
Robertson et al. Serological characteristics of avian reoviruses of Australian origin
Ganapathy et al. A comparison of methods of inducing lachrymation and tear collection in chickens for detection of virus-specific immuoglobulins after infection with infectious bronchitis virus
BR0308365A (en) Injection dna multiple dna vaccine, poultry egg vaccination method, preparation method for dna multiple dna vaccine, multipurpose in ovo injection dna vaccine and poultry egg vaccination method
CA2366056A1 (en) Non-spreading pestivirus
van den Bergh et al. Complete genome sequences of five bluetongue virus (BTV) vaccine strains from a commercial live attenuated vaccine, a BTV-4 field strain from South Africa, and a reassortant strain isolated from experimentally vaccinated cattle
Imagawa Propagation of rinderpest virus in suckling mice and its comparison to murine adapted strains of measles and distemper
Toro et al. Lachrymal antibody response of specific pathogen free chickens and chickens with maternal immunity after infectious bronchitis virus vaccination

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20101214

Year of fee payment: 15

EXPY Expiration of term